Patents Issued in August 30, 2016
  • Patent number: 9427405
    Abstract: Novel liposomes are described which are capable of effectively binding beta amyloid peptide and are useful for the treatment, prevention and diagnosis of Alzheimer's disease. Binding ability is provided by the presence in the formulation of particular natural lipids identified by the Applicant. These comprise a constant component, made up of cholesterol and sphingomyelin, and an additional variable component, made up of selected lipids.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: August 30, 2016
    Assignee: Universita degli Studi de Milano-Bicocca
    Inventors: Massimo Masserini, Francesca Re, Maria Silvia Sesana
  • Patent number: 9427406
    Abstract: A substantially monodisperse assemblage of particles 10 having interconnected pores 20 and a core 30 with at least one shell 40, 60 disposed about the core 30 as well as a method for their synthesis is disclosed.
    Type: Grant
    Filed: October 11, 2014
    Date of Patent: August 30, 2016
    Assignee: Nautilus Capital Corporation
    Inventors: Andrey Gavryushin, Johannes Kobler, Juergen Sauer
  • Patent number: 9427407
    Abstract: Pharmaceutical compositions are provided which comprise effective amounts of analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: August 30, 2016
    Assignee: LOCL PHARMA, INC.
    Inventor: Paul Bosse
  • Patent number: 9427408
    Abstract: The present invention provides compositions for encapsulation of biomaterials in a silica-matrix. The present invention also provides methods of making silica-matrix encapsulated biomaterials, and to methods of using silica-matrix encapsulated biomaterials. In one embodiment, the present invention provides a method of encapsulating mammalian cells in a silica-matrix while maintaining metabolic activity. In another embodiment, the present invention provides a method of purifying cancer cells using a silica-matrix.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: August 30, 2016
    Inventors: Eduardo Reategui, Lisa Kasinkas, Alptekin Aksan
  • Patent number: 9427409
    Abstract: Described is a controlled-release formulation for treating disturbed sleep or insomnia in a subject. The formulation is formulated to release a compound or combination of compounds in sequence at multiple stages.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: August 30, 2016
    Assignee: Sequential Medicine Limited
    Inventor: Lan Bo Chen
  • Patent number: 9427410
    Abstract: A method of producing particles of materials includes, with a first substance that includes at least one component that is a gas at room temperature and atmospheric pressure, extruding or emulsifying the first substance into or in the presence of a second substance to create a bubble in which the first substance is encapsulated by the second substance and wherein at least some of the first substance is in a gaseous phase, and causing the first substance to condense to a liquid phase, which causes the bubble to transform into a droplet or emulsion. The droplet or emulsion so created is an activatable phase change agent that is stable at room temperature and pressure.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: August 30, 2016
    Assignees: The University of North Carolina at Chapel Hill, The Arizona Board of Regents on Behalf of The University of Arizona, The Regents of the University of Colorado
    Inventors: Paul A. Dayton, Paul S. Sheeran, Terry O. Matsunaga, Mark A. Borden
  • Patent number: 9427411
    Abstract: The present invention relates to an antimicrobial topical composition and process for making such composition. The composition comprises of ionic silver, silver nanoparticles, and oxygen, combined within a gel medium and applied topically. The composition optimizes the ionic silver and silver nanoparticle ratio providing for sufficient ionic silver to be delivered as an immediate antimicrobial agent, and sufficient nanoparticle silver to provide time release for conversion to silver ions for continuing antimicrobial effectiveness.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: August 30, 2016
    Inventor: JoAnna M. Esty
  • Patent number: 9427412
    Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: August 30, 2016
    Assignee: Cynapsus Therapeutics, Inc.
    Inventors: Nathan John Bryson, Anthony John Giovinazzo, Scott David Barnhart, Michael Clinton Koons
  • Patent number: 9427413
    Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: August 30, 2016
    Assignee: OncoImmune, Inc.
    Inventors: Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
  • Patent number: 9427414
    Abstract: The present invention concerns a method of enhancing milk production by a ruminant that includes providing a feed that contains sorbitol and at least one additional feed component, and orally feeding the feed to the ruminant, the ruminant ingesting about 100 grams, or less, of sorbitol per day.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: August 30, 2016
    Assignee: LAND O'LAKES, INC.
    Inventor: Cindie M. Luhman
  • Patent number: 9427415
    Abstract: Compounds and methods for modifying sensory perception associated with transient sensory receptors TRPA1, TRPV1, and TRPA1V1. A method for screening compounds for modulation of TRPA1, TRPV1, and/or TRPA1V1. Compositions comprising TRPA1V1 agonists or antagonists, for modifying sensory perception of the compositions.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: August 30, 2016
    Assignee: The Procter & Gamble Company
    Inventors: Koti Tatachar Sreekrishna, Yakang Lin
  • Patent number: 9427416
    Abstract: The invention provides an oil-in-water emulsion useful in the treatment of anorectal disorders comprising a local anesthetic, vasoconstrictor, glycerin and water, and method of preparation of the emulsion and a method for treating hemorrhoids using the composition of the invention.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: August 30, 2016
    Assignee: Wyeth LLC
    Inventors: Gary Robert Agisim, Richard John Kenny, Miron Gerard Still, Ellen Bland Gilliam, Helen Elizabeth Taylor
  • Patent number: 9427417
    Abstract: A process for reducing bacterial colonization in or around the area of a wound includes applying to the area a gel that includes at least one PEG and an aqueous composition which has a pH of from 2 to 4, a total solute concentration of from 1.8 to 4.0 Osm/L, and from 0.9 to 1.7 g/L of at least one cationic surfactant. The aqueous composition can include a buffer system that includes an organic acid and a salt of an organic acid. The gel is effective even when free of materials having antimicrobial properties other than those provided by the aqueous composition, such as sporicides, antifungals and antibiotics.
    Type: Grant
    Filed: March 19, 2016
    Date of Patent: August 30, 2016
    Assignee: Next Science, LLC
    Inventor: Matthew Franco Myntti
  • Patent number: 9427418
    Abstract: The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, and castration-resistant prostate cancer (CRPC) and palliative treatment of prostate cancer, advanced prostate cancer and castration-resistant prostate cancer (CRPC). The compounds of this invention suppress free or total testosterone levels to castrate levels which may be used to treat prostate cancer, advanced prostate cancer, and CRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: August 30, 2016
    Assignee: GTX, INC.
    Inventors: James T. Dalton, Mitchell S. Steiner, Ronald A. Morton
  • Patent number: 9427419
    Abstract: The invention relates generally to compositions comprising dimethylsulfoxide (DMSO) and associated compounds in combination with one or more of the following: fructose 1,6-diphosphate, L-arginine, L-lysine, L-aspartate, and urea. Methods for treating traumatic brain injury, ischemic stroke, atherosclerosis, spinal cord trauma, and neurodegenerative illnesses are also provided.
    Type: Grant
    Filed: September 11, 2006
    Date of Patent: August 30, 2016
    Assignee: Abela Pharmaceuticals, Inc.
    Inventor: Jack De La Torre
  • Patent number: 9427420
    Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: August 30, 2016
    Assignee: Synchroneuron, Inc.
    Inventors: Barry S. Fogel, William D. Kerns, Kei-Lai Fong, San-Laung Chow, Edward Lin, David Wong
  • Patent number: 9427421
    Abstract: Effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine and a method of treating acetaminophen poisoning with effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine are described.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: August 30, 2016
    Assignee: ALPEX PHARMA S.A.
    Inventors: Federico Stroppolo, Gabriele Granata, Shahbaz S. Ardalan
  • Patent number: 9427422
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: August 30, 2016
    Assignee: Infirst Healthcare Limited
    Inventors: Robin Mark Bannister, John Brew, Suzanne Jane Dilly, Gregory Alan Stoloff, Wilson Caparros-Wanderley
  • Patent number: 9427423
    Abstract: The present invention is directed toward fatty acid-based particles, and methods of making such particles. The particles can be associated with an additional, therapeutic agent. Also provided herein is a method of forming fatty acid particles, comprising associating a cross-linked, fatty acid-derived biomaterial with a cryogenic liquid; and fragmenting the bio material/cryogenic liquid composition, such that fatty acid particles are formed. The particles can be used for a variety of therapeutic applications.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: August 30, 2016
    Assignee: ATRIUM MEDICAL CORPORATION
    Inventors: Thomas M. Swanick, Joseph Ferraro, Lisa Rogers, Paul Martakos
  • Patent number: 9427424
    Abstract: The invention provides a method of changing a ratio of 68 to 64 kDa protein of MRJP3 in a royal jelly, a method of producing a royal jelly comprising MRJP3 having a changed ratio of 68 to 64 kDa protein relative to a control royal jelly and the royal jelly produced thereform. Also provided is a method of promoting the growth of the larva of a queen bee comprising feeding the larva of the queen bee a royal jelly of the invention. Further provided is a method of producing bee larva, pupa and queen bees with sizes larger than normal.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: August 30, 2016
    Assignee: Naturewise Biotech & Medicals Corporation
    Inventors: Chung-Yang Huang, Chia-Nan Chen, Wei-Jung Chen, Wei-Jan Huang, Li-Ling Chi
  • Patent number: 9427425
    Abstract: The current disclosure discloses acetogenin(s), extract(s)/fraction(s) standardized to acetogenin(s) comprising terminal ?,?-unsaturated-?-methyl-?-lactone moiety derived from Annona squamosa or their compositions for prevention, treatment, inhibition or controlling inflammation and immune related diseases or disorders mediated through cytokines/chemokines or other biomarkers. The disclosure further discloses said Annona squamosa derived acetogenin(s), extract(s)/fraction(s) or their compositions for prevention, treatment, inhibition or controlling metabolic diseases/disorders.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: August 30, 2016
    Assignee: LAILA NUTRACEUTICALS
    Inventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Venkata Kanaka Ranga Raju Gokaraju, Trimurtulu Golakoti, Krishanu Sengupta, Kiran Bhupathiraju
  • Patent number: 9427426
    Abstract: Indication of use of erdosteine as antidote in a large number of intoxications, especially in heavy metals like lead or mercury, and paracetamol. Indication of use of erdosteine as prophylaxis for intoxications. Erdosteine can be administered per os or intravenous, using a solution obtained with sodium hydrogen carbonate and bidistilled water.
    Type: Grant
    Filed: August 13, 2009
    Date of Patent: August 30, 2016
    Assignee: RAFIFARM S.R.L.
    Inventors: Marco Peretto, Cristina Sarbulescu, Victor Voicu
  • Patent number: 9427427
    Abstract: The invention relates to solid dispersions of poorly water soluble compounds, in particular Compound A as disclosed herein, formed by solvent co-precipitation or spray drying, resulting in improved bioavailability, safety and tolerability of said compounds.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: August 30, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Steve Lomuscio, Hua Ma, Michael Allen Matchett, Harpreet K. Sandhu, Navnit Hargovindas Shah, Yu-E Zhang
  • Patent number: 9427428
    Abstract: Inhibitors of HCV replication of formula I including stereochemically isomeric forms, and salts, solvates thereof, wherein R and R? are, each independently, —CR1R2R3, aryl, heteroaryl or heteroC4-6cycloalkyl, whereby aryl and heteroaryl may optionally be substituted with 1 or 2 substituents selected from halo and methyl. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: August 30, 2016
    Assignee: Janssen Sciences Ireland UC
    Inventors: Koen Vandyck, Stefaan Julien Last, Ioannis Nicolaos Houpis, Pierre Jean-Marie Bernard Raboisson
  • Patent number: 9427429
    Abstract: The present invention provides a method for imaging a disease or condition in a mammal which includes the steps of; administering a therapeutically effective amount of a cell cycle inhibitor to effectively stop proliferation of eukaryotic cells at a cell cycle checkpoint between the G1 and S phase, stopping administration of the cell cycle inhibitor for a period of time, administering a marker to the mammal and imaging the mammal.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: August 30, 2016
    Assignee: Tau Therapeutics LLC
    Inventor: Lloyd S. Gray
  • Patent number: 9427430
    Abstract: A compression therapy apparatus and a method for manufacturing and applying compression with the same may include a bandage and a tension indicator coupled to the bandage. A tension indicator may include a film having layers of liquid crystal droplets deposited on a polymer matrix. The tension indicator can be adapted to color shift under tension between the first end and the second end of the bandage.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: August 30, 2016
    Assignee: KCI Licensing, Inc.
    Inventors: Benjamin Stokes, Timothy Mark Robinson
  • Patent number: 9427431
    Abstract: The present invention makes availables assays and reagents inhibiting paracrine and/or autocrine signals produced by a hedgehog protein or aberrant activation of a hedgehog signal transduction pathway, e.g., which involve the use of a steroidal alkaloid or other small molecule.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: August 30, 2016
    Assignee: Johns Hopkins University School of Medicine
    Inventors: Philip A. Beachy, Michael K. Cooper, Jefferey A. Porter
  • Patent number: 9427432
    Abstract: Pharmaceutical compositions comprising berberine for treatment of skin disorders and methods of use thereof.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: August 30, 2016
    Assignee: TWi Biotechnology, Inc.
    Inventors: Pao-Li Wang, Way-Yu Lin, Chen-Mao Lin, Po-Yuan Tseng
  • Patent number: 9427433
    Abstract: Methods and compositions for enhancing fertility and/or inhibiting pregnancy failure, restoring glucose tolerance and/or preventing glucose intolerance and/or maintaining glucose homeostasis and/or inducing or enhancing weight loss, treating dyslipidemia, treating hypertestosteronism or hyperandrogenism, and/or treating type 2 diabetes in an individual in need thereof are provided. These involve compositions that inhibit expression of interferon-gamma (IFN-?) or a downstream IFN-?-stimulated gene, which is preferably a macrolide immunosuppressant compound.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: August 30, 2016
    Assignee: Queen's University at Kingston
    Inventors: Ahmad J. H. Albaghdadi, Frederick W. K. Kan
  • Patent number: 9427434
    Abstract: The present invention provides a preparation containing pioglitazone or a salt thereof as an active ingredient, which shows high bioavailability of pioglitazone and less interindividual variation in blood drug concentration, as well as a preparation with suppressed color change during preservation. The preparation contains a core containing a pharmaceutically acceptable organic acid with water solubility at 20° C. of not less than 10 mg/mL and pKa1 (a negative common logarithm of the first acid dissociation constant Ka1) at 25° C. of not more than 5, and a coating layer containing pioglitazone or a salt thereof. The coating layer may further contain mannitol or trehalose.
    Type: Grant
    Filed: July 10, 2008
    Date of Patent: August 30, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Hiroto Bando, Yoshihiro Omachi, Kenichiro Kiyoshima
  • Patent number: 9427435
    Abstract: Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and a surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: August 30, 2016
    Assignees: Teikoku Pharma USA, Inc., Techno Guard Co., Ltd.
    Inventors: Kiichiro Nabeta, Toru Hibi
  • Patent number: 9427436
    Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: August 30, 2016
    Assignee: Pharnext
    Inventors: Daniel Cohen, Serguei Nabirochkin, Ilya Chumakov
  • Patent number: 9427437
    Abstract: This invention provides compositions and methods of inhibiting, suppressing, or treating a tendinous or musculoskeletal soft tissue injury. The invention further provides a method of ameliorating symptoms associated with a tendinous or musculoskeletal soft tissue injury. Additionally, the invention provides methods for evaluating the risk of developing a tendinous or musculoskeletal soft tissue injury.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: August 30, 2016
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Joseph A. Abboud, Louis J. Soslowsky
  • Patent number: 9427438
    Abstract: The present invention provides compositions for reducing amyloid plaque burden associated with Alzheimer's disease and methods of using the same.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: August 30, 2016
    Assignee: EIP Pharma, LLC
    Inventor: John Jahangir Alam
  • Patent number: 9427439
    Abstract: The present invention provides methods and compositions for promoting recovery of function from neurologic injury, such as ischemic injury caused by acute stroke.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: August 30, 2016
    Assignee: EIP Pharma, LLC
    Inventor: John Jahangir Alam
  • Patent number: 9427440
    Abstract: Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R1, R2, R4, R5, R6 and R7 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 30, 2016
    Assignee: Janssen Sciences Ireland UC
    Inventors: Sandrine Marie Helene Vendeville, Pierre Jean-Marie Bernard Raboisson, Tse-I Lin, Abdellah Tahri, Katie Ingrid Eduard Amssoms
  • Patent number: 9427441
    Abstract: Methods for reducing intraocular pressure and treating glaucoma are disclosed. The methods include administering to an individual a composition comprising a TRPV4 agonist.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: August 30, 2016
    Assignee: Indiana University Research and Technology Corporation
    Inventor: Yang Sun
  • Patent number: 9427442
    Abstract: Disclosed are compounds of Formula (I): (Formula (I)) wherein: R1 is —CH2CH2CF3; R2 is —CH2CH2CH2F, —CH2CF2CH3, —CH2CH2CF3, —CH2CH(CH3)CF3, —CH2CH2CF2CH3, (Formulae (II), (III), (IV), (V) or (VI): R3 is H or —CH3; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: August 30, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yufen Zhao, Ashvinikumar V. Gavai, Patrice Gill, Soong-Hoon Kim, Brian E. Fink, Libing Chen, Mark G. Saulnier, Wen-Ching Han
  • Patent number: 9427443
    Abstract: A stable anaesthetic composition is described which is particularly suitable for use in cats and dogs. The composition comprises an aqueous solution of an anaesthetically effective amount of water soluble cyclodextrin or a cyclodextrin derivative complex of alfaxalone and a bugger, excluding phosphate buffer pH 7.0, 0.1 M mixed as defined in the British Pharmacopoeia 1998, such that the pH of the solution is from 6.0-8.0.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: August 30, 2016
    Assignee: Jurox Pty. Ltd.
    Inventors: Peter John Kieran, Kai Kin Lau, Barry Edward Patten
  • Patent number: 9427444
    Abstract: This invention relates to biology and medicine and in particular it can be used in medicine for preparation of pharmaceutical composition that can accelerate wound healing by means of directed transport of biologically active substances (bioactive compounds) to the mitochondria, using hydrogen electrochemical potential in mitochondria. Besides, this invention relates to a certain method of influencing on the organism by means of said directed transport of required biologically active substances.
    Type: Grant
    Filed: January 29, 2007
    Date of Patent: August 30, 2016
    Assignee: MITOTECH SA
    Inventors: Vladimir P. Skulachev, Maxim V. Skulachev
  • Patent number: 9427445
    Abstract: The invention pertains to the use of a composition in reducing the number of infections episodes and the occurrence of infections in young children, said composition comprising: (a) long chain polyunsaturated fatty acids, wherein the amount of arachidonic acid is less than 0.06 gram per 100 gram fatty acid; and comprising, per 100 g fatty acids: (i) 0.3-0.6 gram docosahexaenoic acid; (ii) 0.2-0.4 gram eicosapentaenoic acid; and (b) between 1.5 and 2.5 gram indigestible oligosaccharides per 100 kcal, comprising: (i) 1.4-2 gram short-chain galactooligosaccharides; and (ii) 0.1-0.5 gram long-chain fructopolysaccharides.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: August 30, 2016
    Assignee: N.V. Nutricia
    Inventors: Johannes Wilhelmus Christina Sijben, Martine Sandra Alles
  • Patent number: 9427446
    Abstract: The invention relates to a stable injectable aqueous solution containing diclofenac and thiocolchicoside, or pharmaceutically acceptable salts thereof, and the use thereof in the treatment of painful and inflammatory rheumatic or traumatic conditions of the joints, muscles, tendons and ligaments.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: August 30, 2016
    Assignee: EPIFARMA S.R.L.
    Inventors: Giuseppe Irianni, Cristina Macelloni, Luca Teseschi
  • Patent number: 9427447
    Abstract: A compound for use in the treatment or prophylaxis of viral infections such, for example as chicken pox or shingles caused by the Varicella Zoster virus, said compound having the general formula (II): wherein X is O, S, NH or CH2, Y is O, S or NH, Z is O, S or CH2, R1 is C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl, and one of R2 and R3 is OH, and the other of R3 and R2 is a neutral, non-polar amino acid moiety, or a pharmaceutically acceptable salt or hydrate thereof. Said neutral, non-polar amino acid moiety R2 or R3 may be (IV): in which R4, R5, R6 and R7 are each independently H or C1-2 alkyl. In preferred embodiments, one of R2 or R3 is valine, leucine, isoleucine or alanine, particularly valine.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: August 30, 2016
    Assignees: University College Cardiff Consultants Limited, K.U. Leuven Research and Development
    Inventors: Christopher McGuigan, Jan Balzarini, Marco Migliore
  • Patent number: 9427448
    Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.
    Type: Grant
    Filed: March 9, 2013
    Date of Patent: August 30, 2016
    Assignee: The Medicines Company
    Inventors: Clive Arthur Arculus-Meanwell, Simona Skerjanec, Jayne Prats
  • Patent number: 9427449
    Abstract: Administration of low molecular weight (10,000-20,000 Daltons, or lower) pectins, particularly modified citrus pectins (MCP), like PectaSol-C reduces galectins-3 levels in vivo. Reduction of galectin-3 levels by MCP inhibits inflammation, inhibits fibrosis formation in organs and tissues, and inhibits cancer formation, progression, transformation and metastases. The reduction in circulating, serum and cellular galectin-3, inherently resulting from the administration of MCP, provides benefit over a spectrum of biological conditions, as evidenced by in vivo trials.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: August 30, 2016
    Assignee: ECONUGENICS, INC.
    Inventor: Isaac Eliaz
  • Patent number: 9427450
    Abstract: Disclosed are methods, compositions of matter, and protocols useful for the induction of a therapeutic immune modulatory response through administration of exosomes derived from a stem cell source. In one embodiment, said stem cell source is endometrial regenerative cells. Specifically, in one embodiment stem cell derived exosomes are used as a method of treating an autoimmune condition such as rheumatoid arthritis, multiple sclerosis, or systemic lupus erythromatosis.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: August 30, 2016
    Assignee: XON Cells, Inc.
    Inventors: Thomas Ichim, Vladimir Bogin
  • Patent number: 9427452
    Abstract: A method for preparing fermentation broth of fruits and vegetables includes steps of mixing fruits, vegetables, bacteria liquid of Lactobacillus acidophilus, bacteria liquid of Bifidobactreium longum, bacteria liquid of Lactobacillus delbrueckii subsp. bulgaricus, and bacteria liquid of Streptococcus thermophilus, and processing fermentation to obtain the fermentation broth of fruits and vegetables. A fermenting course of the method could be controlled, and a fermenting period is reduced to 15 days.
    Type: Grant
    Filed: July 20, 2013
    Date of Patent: August 30, 2016
    Assignee: Jilin Zixin Pharmaceutical Research Institution LLC.
    Inventors: Dejun Sun, Jinlong Yin, Miaonan Sun, Yizhuo Zhao, Chunsheng Guo, Yanhui Gao, Xue Li
  • Patent number: 9427453
    Abstract: In one embodiment, a method is provided for lowering C-reactive protein levels in a mammal. The method comprises administering a composition containing an effective amount of Irvingia gabonensis seed to a mammal to reduce C-reactive protein levels in the mammal. Other embodiments include, among other things, lowering leptin levels, increasing adiponectin levels, reducing body weight, decreasing LDL and total cholesterol levels, increasing fat loss, and reducing waist size in a mammal using administering a composition containing an effective amount of Irvingia gabonensis.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: August 30, 2016
    Inventor: Julius Enyoug Oben
  • Patent number: 9427454
    Abstract: A method of making liquid olive leaf extract that includes the mixing ground olive leaf, water, and an acid in a container. Once mixed heating the mixture a predetermined temperature for approximately four hours. Next raising the pH to approximately 4.0 and then adding a predetermined amount of cellulase and invertase to the mixture. Then the mixture is mixed for a predetermined period of time. After mixing, sediment is remove from the mixture and the pH is adjusted to approximately 3.0. The mixture is then reduced to a concentrate.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: August 30, 2016
    Inventor: Robert den Hoed
  • Patent number: 9427455
    Abstract: The invention refers to the use of the PAT nonapeptide which is a thymuline analog in the treatment of autoimmune diseases, in particular of rheumatoid arthritis and intestinal bowel diseases (IBD) such as the Crohn's disease.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: August 30, 2016
    Assignee: CLL PHARMA
    Inventors: Jamal Temsamani, Claude Laruelle